Plasma Cell Neoplasm Cell Models for Research

Plasma cell neoplasms, primarily multiple myeloma (MM), account for approximately 1.8% of all cancers and 17% of hematologic malignancies in the United States. The American Cancer Society estimates 35,780 new cases and 12,540 deaths in 2024. Globally, the WHO reported an age-standardized incidence rate of 1.8 per 100,000 in 2022, with higher rates in developed countries. The 5-year relative survival for MM is 59.8% (2014-2020, SEER), but it varies significantly by stage: localized (77%), regional (79%), and distant (58%). Despite advances with proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, most patients relapse, underscoring the need for better preclinical models.

Plasma cell neoplasms are ideal for mechanistic studies due to their well-defined clonal evolution, recurrent genetic alterations, and the availability of numerous public datasets (e.g., TCGA, COSMIC, DepMap). Key open questions include the role of the bone marrow microenvironment in drug resistance, the functional impact of specific mutations (e.g., KRAS, TP53), and the development of synthetic lethality strategies. Gene-edited cell models enable precise dissection of these mechanisms, providing isogenic controls that eliminate confounding genetic background effects.

Plasma cell neoplasms arise from post-germinal center B cells and involve multiple oncogenic pathways:

1. NF-κB pathway: Constitutive activation via mutations in TRAF3, CYLD, or BIRC2/3, leading to enhanced survival and proliferation.

2. RAS/MAPK pathway: Activating mutations in KRAS, NRAS, or BRAF drive uncontrolled cell growth.

3. PI3K/AKT/mTOR pathway: Deregulation through PTEN loss or PIK3CA mutations promotes survival and drug resistance.

4. Cell cycle regulation: Dysregulation of CCND1/CCND2 translocations or TP53 inactivation leads to uncontrolled proliferation.

These pathways are not mutually exclusive and often cooperate to drive disease progression.

Data from TCGA (Nature 2014) and COSMIC (v100).

Key signaling networks in plasma cell neoplasms:

• • NF-κB: Involves upstream activators (TRAF3, CYLD) and downstream targets (BCL2, XIAP). Mutations in negative regulators lead to constitutive activation.
• • RAS/MAPK: KRAS and NRAS mutations activate RAF/MEK/ERK cascade, promoting proliferation and survival.
• • PI3K/AKT: PTEN loss or PIK3CA mutations activate AKT, enhancing survival and drug resistance.
• • JAK/STAT: IL-6 signaling through JAK/STAT3 is critical for plasma cell survival, often overexpressed in the bone marrow microenvironment.
• • Wnt/β-catenin: Aberrant activation promotes self-renewal and drug resistance, though less common than in solid tumors.

These networks provide multiple targets for therapeutic intervention and gene-editing strategies.

Organoid models, though less established for MM, are emerging as 3D cultures that better recapitulate the bone marrow microenvironment, including stromal cell interactions and hypoxia. They are useful for drug testing and studying tumor heterogeneity.

Animal models for plasma cell neoplasms include:

• • Patient-derived xenografts (PDX): Immunodeficient mice (e.g., NSG) engrafted with patient MM cells. They preserve tumor heterogeneity and are useful for drug efficacy studies.
• • Genetically engineered mouse models (GEMM): Vk*MYC mice develop spontaneous MM-like disease with MYC dysregulation. Other models include Eμ-XBP1s and IL-6 transgenic mice.
• • Induced models: Injection of myeloma cell lines (e.g., 5T33MM) into syngeneic mice to study immune interactions.

These models are valuable but have limitations in recapitulating the human bone marrow niche and genetic complexity.

CRISPR-based gene editing has revolutionized plasma cell neoplasm research by enabling the creation of isogenic cell lines with specific genetic alterations. These models are generated by introducing precise knockouts (e.g., TP53, KRAS) or knock-ins (e.g., KRAS G12D) into commonly used cell lines like MM.1S or RPMI-8226. Isogenic pairs (edited vs. parental) allow researchers to attribute phenotypic differences directly to the genetic change, eliminating background effects. Commercially available, sequence-verified models accelerate research by providing validated tools, but it is essential to verify editing efficiency and off-target effects. Examples include TP53 knockout MM.1S cells for studying genomic instability and drug resistance, and KRAS G12D knock-in models for testing RAS pathway inhibitors.

Gene-edited cell models are pivotal for functional genomics. For example:

• • TP53 knockout in MM.1S cells demonstrates loss of cell cycle checkpoint control, increasing sensitivity to DNA-damaging agents.
• • KRAS G12D knock-in in RPMI-8226 cells activates the MAPK pathway, enabling studies of downstream signaling and potential therapeutic targets.
• • NRAS knockout in U266 cells reduces proliferation, confirming its oncogenic dependency.

These models allow high-throughput CRISPR screens to identify synthetic lethal partners, such as targeting PRMT5 in TP53-mutant cells.

Isogenic pairs are ideal for drug screening and resistance studies:

• • Screening: Comparing dose-response curves between edited and parental cells identifies compounds that specifically target the mutation (e.g., KRAS G12C inhibitors in knock-in models).
• • Resistance: Chronic exposure to drugs (e.g., bortezomib) in gene-edited cells can select for resistant clones, revealing mechanisms such as upregulation of efflux pumps or activation of alternative survival pathways.

For example, TP53 knockout cells show reduced sensitivity to p53-dependent apoptosis, mimicking clinical resistance.

CRISPR-based synthetic lethality screens in gene-edited cells can uncover novel biomarkers:

• • Synthetic lethality: In KRAS-mutant cells, knocking out genes like TBK1 or GATA2 leads to cell death, identifying potential therapeutic targets.
• • Biomarker validation: Gene-edited models can validate candidate biomarkers by modulating their expression and assessing correlation with drug response.

For instance, loss of TRAF3 in gene-edited cells increases NF-κB activity, which can be used as a biomarker for sensitivity to proteasome inhibitors.